New York, NY…..The U.S. Food and Drug Administration has approved the marketing of Ampyra™ (dalfampridine, formerly known as fampridine SR, from Acorda Therapeutics) for its ability to improve walking speed in people with any type of multiple sclerosis.
Ampyra is the first therapy specifically approved to treat a symptom of MS, and as an oral drug it represents a big step forward for many people who may benefit from its use. Ampyra is also the first new FDA approved therapy for MS since 2004.
Read the entire story at http://www.msviewsandnews.org/
